Navigation Links
miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease
Date:12/11/2009

BOULDER, Colo., December 10, 2009 miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced the publication of data demonstrating that microRNA-206 (miR-206) plays a crucial role in the progression of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and in neuromuscular synaptic regeneration in mice. The findings, published in the December 11 issue of the journal Science, reveal miR-206 as a potential target for the development of therapeutic agents for the treatment of neuromuscular disease. The study was conducted by researchers led by Eric N. Olson, Ph.D., at the University of Texas Southwestern Medical Center. miRagen is the exclusive licensee of intellectual property (IP) rights related to this discovery, which are part of the Company's extensive estate of enabled microRNA IP.

"This is a breakthrough with significant implications for human health," said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics, Inc. "Currently there are no therapies available to ALS patients that will reverse or delay the onset of muscle atrophy associated with this debilitating disease. Uncovering the essential role of miR-206 in neuromuscular maintenance brings us one step closer to the day when physicians will be able to offer hope to those suffering from ALS and other neuromuscular diseases."

"We are, quite frankly, excited by these findings," said Dr. Olson, Chairman and Professor of Molecular Biology at the University of Texas Southwestern Medical Center and miRagen's Chief Scientific Advisor. "One of the hallmarks of ALS and other similarly degenerative muscle diseases is the inability of the neuromuscular synapse to transmit the impulse that leads to muscle contraction. Our data show that miR-206 plays a central regulatory role in this process. We view this as an ext
'/>"/>

Contact: Tammy Egan
tegan@miragenrx.com
303-531-5952 x107
miRagen Therapeutics, Inc.
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... , ... new market research report is available in its catalogue: ... , http://www.reportlinker.com/p0164232/Neurostimulation---A-Global-Market-Perspective.html , The world neurostimulation ... population, and the resultant rise in age-related diseases such ...
... Dec. 2 The world,s first concept demonstration ... a petrochemically produced ingredient in the manufacture of synthetic rubber ... week. One tire will be on display at a lounge ... throughout December 21, while the other tire will make appearances ...
... LELYSTAD, The Netherlands, December 2 Pepscan ... for the generation of immune therapeutics today announced that it,has ... , Dr. Mol will be responsible ... strategic direction of the company. He brings to,Pepscan more than ...
Cached Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Dutch Biotech Company Pepscan Appoints New CEO 2
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... BETHESDA, Md. (July 24, 2012)Childhood obesity has nearly tripled in ... those 2-19 years of age were classified as obese. If ... likely that today,s children could be the first generation in ... due to the epidemic of childhood obesity which leads to ...
... antimicrobial peptides, are made in immune system cells and epithelial ... gut). One of these peptides, human neutrophil peptide 1, ... works remains unclear. HIV entry into mature ... attachment of the virus to specific targets on T-helper cells, ...
... that convert electricity into methane gas could become an ... Stanford and Pennsylvania State universities. Researchers at both ... have the remarkable ability to turn electrical energy into ... The scientists, goal is to create large microbial factories ...
Cached Biology News:To understand childhood obesity, researchers look to inactive, fat rats 2To understand childhood obesity, researchers look to inactive, fat rats 3Under the right conditions, peptide blocks HIV infection at multiple points along the way 2Stanford-Penn State scientists use microbes to make 'clean' methane 2Stanford-Penn State scientists use microbes to make 'clean' methane 3Stanford-Penn State scientists use microbes to make 'clean' methane 4
... numbers of samples may be carried out using ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied automatic ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (E6152) or contact ... Dim: H diam. 11.25 ...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
Biology Products: